Authors' recommendations: Ceftaroline fosamil (Zinforo®) is recommended as an option for restricted use within NHS Wales. Ceftaroline fosamil (Zinforo®) should be restricted to use for the treatment of complicated skin and soft tissue infections in patients where methicillin-resistant S. aureus (MRSA) is suspected, only in the following settings: For infections caused by Gram-positive pathogens, only if intravenous (IV) vancomycin or IV teicoplanin is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin or IV linezolid is normally used. For mixed infections caused by common Gram-positive and Gram-negative pathogens (excluding extended-spectrum beta-lactamase-producing organisms, AmpC-producing organisms and non-fermenter Gram-negative organisms, such as Pseudomonas aeruginosa), only if IV vancomycin in combination with IV co-amoxiclav or IV teicoplanin in combination with IV co-amoxiclav is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin in combination with IV co-amoxiclav or IV linezolid in combination with IV co-amoxiclav is normally used. Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of complicated skin and soft tissue infections outside of these settings. Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of community-acquired pneumonia.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/1065

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC